TW200605890A - Pharmaceutical compositions for inhibiting arteriosclerosis - Google Patents

Pharmaceutical compositions for inhibiting arteriosclerosis

Info

Publication number
TW200605890A
TW200605890A TW094125205A TW94125205A TW200605890A TW 200605890 A TW200605890 A TW 200605890A TW 094125205 A TW094125205 A TW 094125205A TW 94125205 A TW94125205 A TW 94125205A TW 200605890 A TW200605890 A TW 200605890A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical compositions
naphthylidine
dihydro
oxo
urea
Prior art date
Application number
TW094125205A
Other languages
Chinese (zh)
Inventor
Toshimori Inaba
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of TW200605890A publication Critical patent/TW200605890A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

The invention relates to a pharmaceutical composition with excellent lipid lowering action and effect for inhibiting progressive of atherosclerosis. The present pharmaceutical composition contains dihydronaphthylidine derivative of N-{1-butyl-4-[3-(3-hydroxypropoxy)phenyl]-2,2-dihydro-2-oxo-1,8-naphthylidine-3-yl}-N'-(2,6-diisopropyl-4-aminophenyl)urea or N-[1-butyl-4-(3-pyridine-3-ylmethoxyphenyl)-2,2-dihydro-2-oxo-1,8-naphthylidine-3-yl]-N'-(2,6-diisopropylphenyl)urea, pharmacologically acceptable salt thereof or pharmacologically acceptable prodrug thereof and HMC-CoA reductase inhibitor.
TW094125205A 2004-07-28 2005-07-26 Pharmaceutical compositions for inhibiting arteriosclerosis TW200605890A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004219502 2004-07-28

Publications (1)

Publication Number Publication Date
TW200605890A true TW200605890A (en) 2006-02-16

Family

ID=35786299

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094125205A TW200605890A (en) 2004-07-28 2005-07-26 Pharmaceutical compositions for inhibiting arteriosclerosis

Country Status (2)

Country Link
TW (1) TW200605890A (en)
WO (1) WO2006011551A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69636783T2 (en) * 1995-11-02 2007-10-18 Warner-Lambert Co. Llc METHOD AND PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION
JP2002145774A (en) * 2000-09-01 2002-05-22 Sankyo Co Ltd Pharmaceutical composition
CN1266150C (en) * 2001-08-23 2006-07-26 大日本住友制药株式会社 1, 2-dihydro-2-oxo-1, 8-naphthyridine derivative
WO2003077896A1 (en) * 2002-03-12 2003-09-25 Merck & Co., Inc. Drug combination therapy
AU2003275633A1 (en) * 2003-10-24 2005-05-11 Sumitomo Pharmaceuticals Co., Ltd. Remedy for hyperlipemia
US20070099891A1 (en) * 2003-12-17 2007-05-03 Kouichi Kino Medicinal compositions and combinations

Also Published As

Publication number Publication date
WO2006011551A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
MY151003A (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
UA94833C2 (en) Substituted bicyclolactams
MX2007005694A (en) Novel betulin derivatives, preparation thereof and use thereof.
EP2286825A3 (en) Melanocortin receptor ligands
TW200722100A (en) A therapeutic agent for a β related disorders
NZ596304A (en) Substituted aminopropionic derivatives as neprilysin inhibitors
PT1940839E (en) Pyridopyrimidinone inhibitors of pi3kalpha
MX2009005604A (en) Spiroketone acetyl-coa carboxylase inhibitors.
TW200612958A (en) Substituted imidazole derivatives
IL182527A0 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
TW200728307A (en) Novel spirochromanone derivatives
RS52823B (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases.
MX2009004746A (en) 1,2,4-triazole derivatives as sigma receptor inhibitors.
MX2007004637A (en) Asymmetric synthesis of dihydrobenzofuran derivatives.
EA200600320A1 (en) γ-CRYSTALLINE FORM OF Ivabradine Hydrochloride, its Method of Production and Pharmaceutical Compositions That It Contains
EA200700566A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING LEVETRIACETES, AND METHODS OF THEIR RECEIVING
ATE493386T1 (en) TRANS-3-AZA-BICYCLO-Ä3.1.0Ü-HEXANE DERIVATIVES
MX2008001606A (en) Substituted piperazines as metabotropic glutamate receptor antagonists.
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
TW200745024A (en) Carboxamide derivatives as muscarinic receptor antagonists
TW200640912A (en) Novel processes for the preparation of a 2H-chromene
TN2012000246A1 (en) Pharmaceutical compositions comprising sigma receptor ligands
TW200745039A (en) Isotopically substituted pantoprazole
ATE413388T1 (en) MUSCARINE ANTAGONISTS
MX2013004162A (en) Pharmaceutical compositions containing a dgat1 inhibitor.